Literature DB >> 17392720

Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.

J Y Ryu1, I S Song, Y E Sunwoo, J H Shon, K H Liu, I J Cha, J G Shin.   

Abstract

To develop and validate an in vivo cocktail method for high-throughput phenotyping of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A, 12 healthy subjects received five probe drugs alone or simultaneously. The in vivo phenotyping index of CYP2C9, the ratio of 8 h urine concentration of losartan to its metabolite after a single administration of losartan, was not significantly different from that obtained using the five-drug cocktail. Similarly, the ratios of [omeprazole]/[5-hydroxyomeprazole] (CYP2C19) and [paraxanthine]/[caffeine] (CYP1A2) in 4 h plasma samples and the log ratio of [dextromethorphan]/[dextrorphan] (CYP2D6) in 8 h urine samples and the 4 h plasma concentrations of midazolam (CYP3A) after single administration or well-established three-drug cocktail of caffeine, omeprazole, and dextromethorphan were not significantly different from those after the new five-drug cocktail. In conclusion, the new five-drug cocktail regimen, named the "Inje cocktail," can be used as a tool to phenotype in vivo enzyme activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A with only 4 h blood sampling and 8 h urine collection following simultaneous administration of the five probe drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392720     DOI: 10.1038/sj.clpt.6100187

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  37 in total

1.  Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.

Authors:  Nicolas Hohmann; Antje Blank; Jürgen Burhenne; Yosuke Suzuki; Gerd Mikus; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2019-08-09       Impact factor: 4.335

2.  Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.

Authors:  Ben D Snyder; Andrew Rowland; Thomas M Polasek; John O Miners; Matthew P Doogue
Journal:  Eur J Clin Pharmacol       Date:  2014-07-17       Impact factor: 2.953

3.  Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.

Authors:  Natacha Lenuzza; Xavier Duval; Grégory Nicolas; Etienne Thévenot; Sylvie Job; Orianne Videau; Céline Narjoz; Marie-Anne Loriot; Philippe Beaune; Laurent Becquemont; France Mentré; Christian Funck-Brentano; Loubna Alavoine; Philippe Arnaud; Marcel Delaforge; Henri Bénech
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-03       Impact factor: 2.441

4.  Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions.

Authors:  Yoshiyuki Shirasaka; Jennifer E Sager; Justin D Lutz; Connie Davis; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2013-04-25       Impact factor: 3.922

5.  Repeated administration of berberine inhibits cytochromes P450 in humans.

Authors:  Ying Guo; Yao Chen; Zhi-Rong Tan; Curtis D Klaassen; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2011-08-26       Impact factor: 2.953

6.  Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.

Authors:  Angela Rowland; Madelé van Dyk; David Warncken; Arduino A Mangoni; Michael J Sorich; Andrew Rowland
Journal:  Br J Clin Pharmacol       Date:  2018-01-10       Impact factor: 4.335

7.  Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism.

Authors:  Jiangquan Zhou; Philip E Empey; Robert R Bies; Patrick M Kochanek; Samuel M Poloyac
Journal:  Drug Metab Dispos       Date:  2011-08-25       Impact factor: 3.922

8.  The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots.

Authors:  Massimiliano Donzelli; Adrian Derungs; Maria-Giovanna Serratore; Christoph Noppen; Lana Nezic; Stephan Krähenbühl; Manuel Haschke
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

9.  Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.

Authors:  Sandrine Turpault; William Brian; Robert Van Horn; Alix Santoni; Franck Poitiers; Yves Donazzolo; Xavier Boulenc
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

10.  Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.

Authors:  Ole Kristian Thu; Olav Spigset; Odd Georg Nilsen; Bent Hellum
Journal:  Eur J Clin Pharmacol       Date:  2015-11-28       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.